Atezolizumab (anti-PD-L1) - Primary antibody, INHIBITOR of Programmed cell death 1 ligand 1 inhibitor

Features and benefits

Short Overview:
Atezolizumab is a humanized monoclonal antibody IgG1, which resists programmed death factor ligand 1 (PD-L1) and is used for cancer research.
Species reactivity(Reacts with): Human

Application:

Item Number

A411996

Grouped product items
SKU	Size	Availability	Price
A411996-1mg	1mg	In stock	$159.90
A411996-5mg	5mg	Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!	$664.90
A411996-10mg	10mg	Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!	$1,196.90
A411996-25mg	25mg	Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!	$2,692.90
A411996-100mg	100mg	Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!	$9,694.90

Atezolizumab is a humanized monoclonal antibody IgG1, which resists programmed death factor ligand 1 (PD-L1) and is used for cancer research.

View related series

Basic Description

Product Name	Atezolizumab (anti-PD-L1) - Primary antibody
Synonyms	MPDL3280A
Specifications & Purity	≥95%, ~60mg/ml(in buffer),98%
Conjugation	Unconjugated
Grade	Moligand™
Action Type	INHIBITOR
Mechanism of action	INHIBITOR of Programmed cell death 1 ligand 1 inhibitor
Product Description	A human, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents binding of this ligand to B7.1 expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of atezolizumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).

Product Properties

Concentration	~60mg/ml(in buffer),98%
Storage Temp	Protected from light,Store at -20°C
Shipped In	Ice chest + Ice pads
Stability And Storage	The diluted protein solution can be stored in cold storage at 2-8 degrees away from light for no more than 2 weeks. Long-term storage is not recommended. Avoid repeated freeze-thaw. The activity of freeze-thaw protein will decrease by about 5% each time.
CAS	1380723-44-3

Certificates

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

7 results found

Lot Number	Certificate Type	Date	Item
ZJ23F0700555	Certificate of Analysis	Jul 14, 2023	A411996
ZJ23F0700554	Certificate of Analysis	Jul 14, 2023	A411996
ZJ23F0700553	Certificate of Analysis	Jul 14, 2023	A411996
ZJ23F0700556	Certificate of Analysis	Jul 14, 2023	A411996
ZJ23F0700552	Certificate of Analysis	Jul 14, 2023	A411996
ZJ23F0200038	Certificate of Analysis	Feb 15, 2023	A411996
ZJ23F0200037	Certificate of Analysis	Feb 15, 2023	A411996

Solution Calculators

Determine the necessary mass, volume, or concentration for preparing a solution.

Determine the dilution needed to prepare a stock solution.

Basic Description